NCT00326170 - Phase II 5-Azacytidine Plus VPA Plus ATRA | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2005

Primary Completion Date

July 31, 2007

Study Completion Date

December 31, 2007

Conditions

Myelodysplastic SyndromeAcute Myelogenous Leukemia

Interventions

DRUG

5-Azacytidine (5-aza)

Start at 75 mg/m\^2 subcutaneously daily for 7 days.

DRUG

Valproic Acid

50 mg/kg daily by mouth for 7 days, same days as 5-aza.

DRUG

All-Trans Retinoic Acid (ATRA)

45 mg/m\^2 orally daily (in two divided doses) for 5 days starting on day 3 of the administration of 5-aza and VPA.

Trial Locations (1)

The University of Texas M.D. Anderson Cancer Center, Houston